Zhejiang Dayang Biotech Group Co
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provide… Read more
Zhejiang Dayang Biotech Group Co (003017) - Total Liabilities
Latest total liabilities as of September 2025: CN¥650.82 Million CNY
Based on the latest financial reports, Zhejiang Dayang Biotech Group Co (003017) has total liabilities worth CN¥650.82 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Dayang Biotech Group Co - Total Liabilities Trend (2013–2024)
This chart illustrates how Zhejiang Dayang Biotech Group Co's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Dayang Biotech Group Co Competitors by Total Liabilities
The table below lists competitors of Zhejiang Dayang Biotech Group Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
China | CN¥1.02 Billion |
|
Television Broadcasts Ltd
PINK:TVBCY
|
USA | $3.46 Billion |
|
Sam Engineering Equipment
KLSE:9822
|
Malaysia | RM565.93 Million |
|
China Shineway Pharmaceutical Group Limited
PINK:CSWYF
|
USA | $2.58 Billion |
|
Guangzhou Jointas Chemical Joint Stock Co Ltd
SHE:002909
|
China | CN¥1.35 Billion |
|
Contrel Technology Co Ltd
TWO:8064
|
Taiwan | NT$2.34 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Zhejiang Dayang Biotech Group Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Dayang Biotech Group Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Dayang Biotech Group Co (2013–2024)
The table below shows the annual total liabilities of Zhejiang Dayang Biotech Group Co from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥600.40 Million | +11.50% |
| 2023-12-31 | CN¥538.47 Million | +2.97% |
| 2022-12-31 | CN¥522.92 Million | +36.31% |
| 2021-12-31 | CN¥383.64 Million | +41.74% |
| 2020-12-31 | CN¥270.67 Million | +83.49% |
| 2019-12-31 | CN¥147.51 Million | -8.37% |
| 2018-12-31 | CN¥160.99 Million | -8.20% |
| 2017-12-31 | CN¥175.37 Million | -26.12% |
| 2016-12-31 | CN¥237.37 Million | -4.72% |
| 2015-12-31 | CN¥249.12 Million | -6.50% |
| 2014-12-31 | CN¥266.43 Million | +4.92% |
| 2013-12-31 | CN¥253.93 Million | -- |